Boston, USA, May 20, 2025 – Cognito Therapeutics, a startup specializing in the development of digital therapeutic solutions for neurodegenerative diseases, today announced the publication of very encouraging results from its Phase II clinical trials of an innovative approach to treating Alzheimers disease. The company is developing a non-invasive device that uses gamma-frequency brain stimulation via audiovisual signals, orchestrated by artificial intelligence algorithms.
The presented data indicate that patients undergoing therapy with the Cognito device experienced a statistically significant slowing of disease progression compared to the control group. Specifically, improvements were noted in cognitive tests related to memory, attention, and executive functions. Furthermore, a reduction in biomarkers associated with pathological processes in Alzheimers disease, such as amyloid plaque and tau protein accumulation, was recorded through cerebrospinal fluid analysis and PET scans in some patients. The therapy also demonstrated a good safety and tolerability profile.
Cognito Therapeutics method is based on the hypothesis that stimulating brain gamma rhythms, which are often disrupted in Alzheimers patients, can help improve neural activity and activate the brains clearance mechanisms for pathological proteins. Artificial intelligence in the system is used to personalize stimulation parameters for each patient, adapting to their individual characteristics and response to therapy in real-time, potentially increasing its effectiveness.
These results open new prospects for the development of non-pharmacological methods for treating and preventing Alzheimers disease, which is one of the most serious health challenges in the worlds aging population. Cognito Therapeutics success could pave the way for broader application of digital therapeutics and AI-driven interventions in neurology. The company plans to discuss the design of the next, Phase III clinical trials with regulatory authorities, including the FDA, in the near future, which will be decisive for the possible market launch of this technology. This offers hope to millions of patients and their families awaiting new effective ways to combat this devastating disease.